Cite
HARVARD Citation
Gadgeel, S. et al. (2018). Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Annals of oncology. pp. 2214-2222. [Online].